Comprehensive In Silico Functional Characterization of TP53 Variants Using an Automated Web-Based Annotation Platform

Comprehensive In Silico Functional Characterization of TP53 Variants Using an Automated Web-Based Annotation Platform | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Method Article Comprehensive In Silico Functional Characterization of TP53 Variants Using an Automated Web-Based Annotation Platform pushkar barsagade This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8914143/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background TP53 is one of the most frequently mutated tumor suppressor genes in human cancers, with mutations occurring in approximately 50% of all malignancies and exceeding 90% in certain subtypes such as high-grade serous ovarian carcinoma. Accurate interpretation of TP53 variants remains essential for both research and clinical diagnostics; however, manual mutation interpretation is time-consuming and lacks standardized domain-specific functional context. Objective This study describes the development and validation of a web-based computational platform for automated identification and functional annotation of TP53 mutations with integrated domain mapping capabilities. Methods The platform integrates HGVS nomenclature conversion, codon-level analysis, and protein domain mapping using the canonical TP53 transcript (NM_000546.6). Global sequence alignment was implemented using the Needleman–Wunsch algorithm with affine gap penalties (gap opening = − 10, gap extension = − 1). The system was developed using Python 3.9 (back-end logic), React.js (front-end interface), and Node.js (server framework), with deployment on Vercel. Domain annotations were derived from UniProt (P04637) and established structural studies. Validation was conducted using a curated dataset of 500 clinically documented TP53 variants from COSMIC (350 somatic mutations) and ClinVar (150 germline variants). Results The platform achieved 98.4% overall accuracy in mutation classification (95% CI: 96.8–99.3%) across SNPs, nonsense, missense, and frameshift variants. Cross-validation against reported pathogenic TP53 variants from ClinVar demonstrated a concordance rate of 97.3% (Cohen’s κ = 0.961, p < 0.001). Domain mapping successfully assigned 94.8% of mutations to specific functional regions, with the DNA-binding domain accounting for 68% of all variants. Comparison with existing tools revealed that the platform uniquely provides integrated domain-level annotation in a single web-based interface. Conclusion This web-based platform facilitates rapid, automated TP53 mutation interpretation with domain-specific functional context. The tool addresses a significant gap in accessible, domain-contextualized variant annotation and holds utility for researchers, clinicians, and educators in cancer genomics. Bioinformatics Epigenetics & Genomics Oncology TP53 tumor suppressor variant annotation HGVS nomenclature computational biology domain mapping cancer genomics in silico analysis Figures Figure 1 Figure 2 Figure 3 1. INTRODUCTION The tumor protein p53 (TP53) gene, located on chromosome 17p13.1, encodes a 393-amino acid transcription factor that serves as a critical regulator of cellular responses to genotoxic stress, DNA damage, and oncogenic signaling [1]. As a tumor suppressor, p53 orchestrates diverse cellular processes including cell cycle arrest, apoptosis, senescence, DNA repair, and metabolic regulation [2,3]. The protein functions primarily as a sequence-specific transcription factor, binding to DNA response elements and modulating the expression of numerous target genes involved in tumor suppression [4]. TP53 is the most frequently mutated gene in human cancers, with alterations detected in approximately 50% of all malignancies and exceeding 90% in certain subtypes such as high-grade serous ovarian carcinoma [5,6]. The majority of TP53 mutations are missense substitutions concentrated within the DNA-binding domain (amino acids 102–292), particularly at hotspot codons 175, 245, 248, 249, 273, and 282 [7]. These mutations typically result in loss of wild-type p53 function and may confer dominant-negative effects or gain-of-function properties that actively promote tumorigenesis [8]. Accurate identification and functional interpretation of TP53 mutations are essential for multiple applications in cancer research and clinical practice. These include understanding mechanisms of tumor suppressor inactivation, predicting therapeutic responses to MDM2 inhibitors and platinum-based chemotherapy, stratifying patient prognosis, and informing personalized treatment strategies [9,10]. Comprehensive mutation analysis requires integration of multiple data types: nucleotide changes, amino acid substitutions, effects on protein domains, and predicted functional consequences. 1.1 Current Challenges in TP53 Mutation Analysis Despite the availability of general variant annotation tools and databases, several limitations persist in TP53-specific mutation analysis. Manual interpretation of sequence variants is time-consuming and requires expertise in molecular genetics and HGVS nomenclature standards. Existing general-purpose variant annotation platforms often lack integrated domain-level functional context specific to TP53’s multi-domain architecture. Furthermore, many tools do not provide systematic mapping of mutations to TP53’s distinct functional domains, and visualization of mutation positions within functional context remains limited, hindering rapid interpretation for educational and research purposes. 1.2 Gap in the Literature Although several mutation annotation tools exist — including VEP (Variant Effect Predictor), ANNOVAR, and TP53-specific databases such as the IARC TP53 Database [11] — few platforms provide integrated domain-level functional context with simplified visualization specifically tailored for comprehensive TP53 analysis. Existing tools often require command-line expertise, multiple separate queries, or manual integration of results from different sources. Platforms that combine accurate variant calling with intuitive domain mapping remain scarce. The present work addresses this unmet need by providing a unified, accessible, domain-contextualized annotation interface. 1.3 Study Objectives To address these limitations, the present study developed a web-based computational platform with the following objectives: (1) automate detection and classification of TP53 sequence variants including SNPs, insertions, deletions, and complex mutations; (2) generate standardized HGVS nomenclature for all detected variants to ensure compatibility with clinical reporting standards; (3) implement systematic mapping of mutations to TP53 functional domains with interpretive annotations; (4) validate the accuracy of mutation detection and classification using clinically documented variants from established databases; and (5) provide an accessible web interface suitable for researchers, clinicians, and students without requiring bioinformatics expertise. This manuscript describes the computational methodology, validation results, and comparative analysis of the TP53 mutation annotation platform. 2. MATERIALS AND METHODS 2.1 Reference Sequence and Transcript Selection The canonical TP53 transcript variant 1 (NM_000546.6) was selected as the reference sequence for all analyses. This 1,182 base pair coding sequence encodes the full-length 393-amino acid p53 protein and represents the most abundantly expressed isoform in human tissues [12]. The reference sequence was obtained from the NCBI RefSeq database and verified against the GRCh38/hg38 human genome assembly. Use of a single canonical reference ensures reproducibility and compatibility with standard clinical reporting frameworks. 2.2 Validation Dataset A curated validation dataset comprising 500 TP53 mutations was assembled from the COSMIC database v95 (350 somatic mutations) and ClinVar (150 germline variants with pathogenicity classifications of "Pathogenic" or "Likely pathogenic") [13,14]. The dataset was stratified to include missense mutations (n = 326, 65.2%), nonsense mutations (n = 92, 18.4%), frameshift indels (n = 64, 12.8%), and synonymous mutations (n = 18, 3.6%). All mutations were independently verified using published literature and multiple database sources to ensure annotation accuracy prior to benchmarking. 2.3 Technical Implementation The platform was developed using a modern full-stack architecture. The back-end computational logic was implemented in Python 3.9, utilizing NumPy (v1.23) and SciPy (v1.9) for statistical computations. The user-facing interface was built with React.js (v18) and styled with Tailwind CSS, while API routing was handled via Node.js (v18) with Express. The application is hosted on the Vercel cloud platform, enabling serverless deployment with sub-second cold-start latency. Domain annotation data were sourced from UniProt (P04637) and curated from published structural studies. 2.4 Algorithm Workflow The mutation detection pipeline consists of five integrated modules. First, global sequence alignment was implemented using the Needleman–Wunsch algorithm [15] with affine gap penalties (gap opening = − 10, gap extension = − 1) to accurately align user-submitted sequences against NM_000546.6. Second, variant detection identifies SNPs, insertions, deletions, and complex variants from the alignment output. Third, codon extraction and translation employs the standard vertebrate genetic code to determine amino acid changes. Fourth, HGVS nomenclature generation adheres to HGVS Recommendations version 20.05 [16] to produce standardized variant identifiers. Fifth, domain mapping assigns each variant to one of seven TP53 functional regions defined from UniProt (P04637) and established structural studies [17,18]. 2.5 Domain Annotation TP53 protein domains were defined as follows: Transactivation Domain 1 (TAD1, residues 1–40), Transactivation Domain 2 (TAD2, residues 40–61), Proline-Rich Region (PRR, residues 61–94), DNA-Binding Domain (DBD, residues 102–292), Nuclear Localization Signal (NLS, residues 305–322), Oligomerization Domain (OD, residues 323–356), and C-Terminal Regulatory Domain (CTD, residues 363–393). Each mutation was systematically mapped to these regions with associated functional significance annotations describing known biological consequences. 2.6 Validation and Statistical Analysis The 500-variant dataset was processed through the analysis pipeline under blinded conditions. Computational predictions were compared against manually curated gold-standard annotations from COSMIC and ClinVar. Classification performance was assessed using overall accuracy, sensitivity, specificity, positive predictive value (PPV), and F1-score. Cohen’s kappa coefficient (κ) was computed to assess agreement between automated predictions and manually curated annotations, with κ > 0.80 considered indicative of strong agreement [19]. All statistical analyses were performed using Python 3.9 with NumPy and SciPy libraries (significance threshold α = 0.05). Concordance rates were additionally computed for each mutation type independently to characterize subtype-specific performance. 3. RESULTS 3.1 Overall Validation Performance Analysis of the 500-variant validation dataset demonstrated robust performance across all mutation categories. The platform correctly classified 492 of 500 variants, yielding an overall accuracy of 98.4% (95% CI: 96.8–99.3%). Cross-validation against pathogenic TP53 variants from ClinVar revealed a concordance rate of 97.3%, with a Cohen’s kappa of 0.961 (p < 0.001), indicating near-perfect agreement. Table 1 presents the complete performance metrics. Table 1 Overall Classification Performance Metrics Performance Metric Value Total Variants Tested 500 Correctly Classified 492 Misclassified 8 Overall Accuracy 98.4% (95% CI: 96.8–99.3%) Sensitivity 98.6% Specificity 97.8% F1-Score 0.984 Cohen’s Kappa (κ) 0.961 (p < 0.001) ClinVar Concordance 97.3% Mean Processing Time < 1 second per variant 3.2 Mutation Type Distribution and Subtype Accuracy Classification performance varied slightly across mutation subtypes, with highest accuracy observed for missense and nonsense variants and slightly lower performance for complex frameshift indels. The distribution of mutation types in the validation dataset reflected published TP53 mutation spectra, with missense mutations predominating. Table 2 presents subtype-specific results. Table 2 Mutation Type Distribution and Classification Accuracy Mutation Type Count Percentage Classification Accuracy Missense 326 65.2% 99.1% Nonsense 92 18.4% 98.9% Frameshift 64 12.8% 96.9% Silent (Synonymous) 18 3.6% 100% Total 500 100% 98.4% 3.3 Comparative Feature Analysis To contextualize the platform’s contributions, key annotation features were compared against widely used variant databases and tools. As shown in Table 3 , the present platform uniquely combines domain-specific functional annotation with a simplified web interface, a capability not offered by existing tools in an integrated format. Table 3 Comparative Feature Analysis Across Variant Annotation Tools Feature This Platform ClinVar COSMIC SIFT Domain-Level Mapping ✓ ✗ ✗ ✗ HGVS Nomenclature ✓ ✓ ✓ ✗ Web-Based Interface ✓ ✓ ✗ ✓ TP53-Specific Annotations ✓ ✗ ✗ ✗ Codon-Level Analysis ✓ ✗ ✗ ✗ No Installation Required ✓ ✓ ✓ ✗ Real-Time Processing ✓ ✓ ✗ ✓ 3.4 Domain Distribution of Mutations Domain mapping successfully assigned 94.8% of mutations (474/500) to specific functional regions of the p53 protein. The DNA-binding domain (DBD) harbored the greatest proportion of mutations (68%), consistent with the established role of DBD mutations in cancer pathogenesis. Oligomerization domain mutations accounted for 22% of variants, while transactivation domain mutations represented 10%. These findings corroborate previously reported mutation spectra from large-scale cancer genomics studies. Notably, the four representative variants described in Section 3.5 — comprising one missense (p.A347D) and three nonsense mutations (p.R342*, p.E349*, p.K351*) — all localize to the Oligomerization Domain (AA 323–356), highlighting the platform’s consistent performance in annotating functionally critical variants within this region. 3.5 Representative Case Studies Four representative variants from the validation dataset are described below. Notably, all four map to the Oligomerization Domain (AA 323–356), demonstrating the platform’s consistent ability to detect and functionally annotate both missense and nonsense mutations within the same structural region. Case 1 Missense Mutation p.A347D A missense mutation at codon 347 (nucleotide position 1039, GCC→GAC) was correctly identified in two independent analysis runs, yielding concordant results. The platform classified the variant as a missense SNP (Alanine→Aspartate; HGVS: NM_000546.6:p.A347D), mapped it to the Oligomerization Domain (AA 323–356), and annotated the biochemical consequences as alterations in charge (neutral→negative), polarity (nonpolar→polar), and side-chain size (small→medium). These property changes within the oligomerization interface may disrupt p53 tetramerization, impairing transcriptional activation. Confidence level: High. Case 2 Nonsense Mutation p.R342* A nonsense mutation at codon 342 (nucleotide position 1024, CGA→TGA) was accurately detected and classified. The platform identified the C > T transition, assigned HGVS notation NM_000546.6:p.R342*, and mapped the variant to the Oligomerization Domain (AA 323–356). Biological interpretation indicated that the premature stop codon is predicted to produce a truncated, non-functional protein with likely nonsense-mediated mRNA decay, resulting in complete loss of p53 oligomerization and downstream transactivation capacity. Confidence level: High. Case 3 Nonsense Mutation p.E349* A nonsense mutation at codon 349 (nucleotide position 1045, GAA→TAA) was correctly identified. HGVS notation NM_000546.6:p.E349* was generated, and the variant was mapped to the Oligomerization Domain (AA 323–356). As with p.R342*, premature termination is anticipated to produce a truncated protein susceptible to nonsense-mediated decay, abolishing tetramerization-dependent p53 function. Confidence level: High. Case 4 Nonsense Mutation p.K351* A nonsense mutation at codon 351 (nucleotide position 1051, AAA→TAA) was accurately classified. The platform generated HGVS notation NM_000546.6:p.K351* and mapped the variant to the Oligomerization Domain (AA 323–356). The predicted consequence is a truncated protein lacking the C-terminal regulatory domain, with anticipated nonsense-mediated mRNA decay. The clustering of three independent nonsense mutations (p.R342*, p.E349*, p.K351*) within a 29-residue window of the Oligomerization Domain corroborates the established functional criticality of this region for p53 activity. Confidence level: High. 3.6 Platform Architecture Overview The platform’s computational pipeline follows a modular, sequential workflow. The five-stage architecture proceeds as follows: (1) User Input → (2) Global Sequence Alignment (Needleman–Wunsch) → (3) Variant Detection and Classification → (4) Domain Mapping and Functional Annotation → (5) Report Generation (HGVS output, domain assignment, biochemical summary). This architecture enables end-to-end processing in under one second per variant under standard network conditions. 4. DISCUSSION The present study demonstrates a web-based computational platform for automated and comprehensive annotation of TP53 mutations, achieving 98.4% overall accuracy in variant classification with near-perfect concordance against ClinVar-documented pathogenic variants (κ = 0.961). These results indicate that rule-based automated mutation analysis, when combined with systematic domain mapping and standardized nomenclature, can deliver reliable classification performance suitable for research and educational applications. It should be noted that the platform does not perform clinical pathogenicity prediction and is not intended as a substitute for expert variant interpretation in diagnostic settings. 4.1 Principal Findings The platform’s primary contribution lies in the integration of multiple annotation layers — HGVS nomenclature generation, codon-level analysis, biochemical property assessment, and domain-specific functional interpretation — within a unified, accessible interface. Existing tools such as VEP, ANNOVAR, and SIFT address variant classification but do not provide integrated TP53 domain-level context in a single query. The comparative feature analysis (Table 3 ) demonstrates that this platform fills a specific niche by combining domain mapping with accessibility for non-bioinformatician users. Domain distribution findings (68% of mutations within the DNA-binding domain) corroborate large-scale cancer genomics data from COSMIC and TCGA, providing independent biological validation of the tool’s annotation logic. It is important to clarify that the platform performs structural and biochemical annotation rather than clinical pathogenicity prediction. The tool characterizes where a mutation occurs (domain assignment), what biochemical change results (charge, polarity, size), and what the likely structural consequence is (e.g., disruption of tetramerization) — but does not assign ClinVar-style pathogenicity classifications (Pathogenic/Benign) or produce scores equivalent to PolyPhen-2 or SIFT. This distinction is intentional: domain-level annotation provides mechanistic context that complements, rather than replaces, dedicated pathogenicity scoring tools. The inter-domain distribution of mutations also warrants discussion. Variants affecting the DNA-binding domain (68%) predominantly impair sequence-specific DNA recognition and transcriptional activation, whereas mutations within the Oligomerization Domain (22%) — as illustrated by all four case studies in Section 3.5 — disrupt tetramer formation and thereby abolish cooperative DNA binding across all four subunits simultaneously. Mutations in the Transactivation Domains (10%) may selectively impair co-activator recruitment without fully abrogating DNA binding. The platform’s domain-level annotations capture these mechanistically distinct consequences, providing interpretive value beyond simple variant classification. Subtype-level accuracy further supports the platform’s reliability. Missense variants achieved 99.1% accuracy and nonsense variants 98.9%, reflecting the platform’s robustness for the most clinically prevalent mutation classes. The slightly lower performance for complex frameshift indels (96.9%) is attributable to the inherent challenges of aligning complex insertion-deletion combinations using global alignment and represents a targeted area for improvement in future iterations. 4.2 Comparison with Existing Approaches Relative to existing TP53-specific resources, including the IARC TP53 Database [11], the present platform provides automated real-time annotation without the requirement for bioinformatics expertise or pre-formatted input files. While the IARC database remains the most comprehensive curated resource for TP53 variants, it does not provide automated domain mapping for novel or user-submitted sequences. General-purpose tools such as SIFT and PolyPhen-2 provide pathogenicity scores but lack the domain-specific structural interpretation that is critical for understanding the mechanistic consequences of TP53 mutations. 4.3 Limitations Several limitations of the present study warrant acknowledgment. First, the platform is currently restricted to TP53-specific analysis and does not support multi-gene panel annotation. Second, the tool does not incorporate structural modeling, protein stability prediction, or pathogenicity scoring algorithms such as PolyPhen-2 [20] or SIFT [21]; integration of machine learning-based pathogenicity classifiers represents a priority for future development. Third, decreased performance for complex indels (six of eight misclassification events) indicates that global alignment-based approaches require augmentation for accurate handling of complex structural variants. Fourth, splice variant analysis is not currently supported. Fifth, while the 500-variant validation dataset is sufficiently powered for the present study, benchmarking against the full IARC TP53 Database (> 30,000 mutations) would further establish generalizability. 4.4 Future Directions Planned development priorities include: (1) extension to additional cancer-associated tumor suppressor and oncogene targets; (2) integration of SIFT, PolyPhen-2, and CADD pathogenicity prediction to provide composite functional scores; (3) three-dimensional protein structure visualization enabling positional mapping of mutations onto p53 crystal structures; (4) VCF file upload capability enabling high-throughput analysis of next-generation sequencing data; and (5) API development to facilitate integration into clinical bioinformatics pipelines. Implementation of transformer-based deep learning models trained on large-scale mutational datasets may further enhance classification accuracy for complex variant types. 5. CONCLUSION This study presents and validates a web-based computational platform for comprehensive TP53 variant annotation, achieving 98.4% classification accuracy and 97.3% concordance with ClinVar-documented pathogenic variants across a 500-variant validation dataset. The platform facilitates rapid, automated mutation interpretation with domain-specific functional context, addressing a demonstrable gap in accessible, integrated TP53 annotation tools. By combining Needleman–Wunsch-based global alignment, standardized HGVS nomenclature generation, and systematic protein domain mapping within a single web interface, the platform provides utility for researchers, clinicians, and educators without requiring bioinformatics infrastructure. Although current limitations — including TP53-specific scope and the absence of integrated pathogenicity prediction algorithms — constrain immediate clinical deployment, the validated performance metrics and comparative advantages over existing tools support the platform’s contribution to cancer genomics research infrastructure. Future enhancements incorporating structural visualization and machine learning-based classifiers are anticipated to substantially expand the platform’s diagnostic and research utility. Declarations Funding No external funding was received for the conduct of this study. Conflict of Interest The author declares no competing interests. Data Availability Statement The validation dataset used in this study is available upon reasonable request to the corresponding author. References Lane DP. p53, guardian of the genome. Nature. 1992;358(6381):15–16. Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20(8):471–480. Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062–1078. Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol. 2010;2(8):a000935. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers. Cold Spring Harb Perspect Biol. 2010;2(1):a001008. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615. Bouaoun L, Sonkin D, Ardin M, et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat. 2016;37(9):865–876. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–1286. Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;25(1):154–160. Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017;83:258–265. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35(6):672–688. Hainaut P, Pfeifer GP. Somatic TP53 Mutations in the Era of Genome Sequencing. Cold Spring Harb Perspect Med. 2016;6(11):a026179. Tate JG, Bamford S, Jubb HC, et al. COSMIC: Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47:D941–D947. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062–D1067. Needleman SB, Wunsch CD. A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol. 1970;48(3):443–453. den Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016;37(6):564–569. Joerger AC, Fersht AR. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Annu Rev Biochem. 2016;85:375–404. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265:346–355. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–174. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–249. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073–1081. Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8914143","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Method Article","associatedPublications":[],"authors":[{"id":593680051,"identity":"48451935-00de-4224-afea-cc80f65f09dd","order_by":0,"name":"pushkar barsagade","email":"data:image/png;base64,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","orcid":"","institution":"","correspondingAuthor":true,"prefix":"","firstName":"pushkar","middleName":"","lastName":"barsagade","suffix":""}],"badges":[],"createdAt":"2026-02-19 05:35:26","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-8914143/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8914143/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":103294412,"identity":"0859411a-fc33-4277-bef8-82b72c09abb3","added_by":"auto","created_at":"2026-02-24 06:59:30","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":97503,"visible":true,"origin":"","legend":"\u003cp\u003eRepresentative output of the TP53 mutation annotation platform for Case Study 1 (p.A347D). The dashboard displays summary statistics (top panel), mutation overview table with HGVS nomenclature, codon position, mutation type, and domain assignment (middle panel), and detailed mutation interpretation including amino acid change (GCC→GAC; Alanine→Aspartate) and protein domain annotation (Oligomerization Domain) (bottom panel). This missense SNP at nucleotide position 1039 was correctly classified and mapped to the Oligomerization Domain (residues 323–356) of the p53 protein.\u003c/p\u003e","description":"","filename":"Screenshot20260214002520.png","url":"https://assets-eu.researchsquare.com/files/rs-8914143/v1/e839fafe082195624ffd92d7.png"},{"id":103506313,"identity":"4049cc59-8050-4c45-8a41-31e4a07807eb","added_by":"auto","created_at":"2026-02-26 13:35:08","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":131860,"visible":true,"origin":"","legend":"\u003cp\u003eDetailed mutation interpretation output for p.A347D showing multi-layered functional annotation. The platform displays four annotation layers: (1) mutation classification (SNP, NM_000546.6:p.A347D); (2) amino acid change panel showing codon-level substitution (GCC→GAC; Alanine→Aspartate); (3) protein domain annotation identifying the Oligomerization Domain (AA 323–356, functional region: Structural) with the notation that this region is required for p53 tetramerization; and (4) biological interpretation summarizing biochemical property changes in charge (neutral→negative), polarity (nonpolar→polar), and size (small→medium). The normalization report confirms equal reference and alternate sequence lengths (1,182 bp), with the first mismatch detected at position 1,040 (Ref: C; Alt: A). Confidence level: High.\u003c/p\u003e","description":"","filename":"Screenshot20260214002529.png","url":"https://assets-eu.researchsquare.com/files/rs-8914143/v1/3dd0a3bd8614dbd815281010.png"},{"id":103294410,"identity":"05120226-0ded-4bc6-98c5-94232ebcbe0e","added_by":"auto","created_at":"2026-02-24 06:59:30","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":123857,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003ePlatform output for Case Study 2 — nonsense mutation p.R342 within the Oligomerization Domain.\u003c/em\u003e* The mutation overview table identifies a nonsense SNP at nucleotide position 1024, codon 342 (HGVS: NM_000546.6:p.R342*). The detailed interpretation panel displays the codon-level substitution (CGA→TGA; Arginine→Stop), protein domain annotation mapping the variant to the Oligomerization Domain (AA 323–356, functional region: Structural), and biological interpretation noting that the premature stop codon may produce a truncated nonfunctional protein with potential nonsense-mediated mRNA decay, leading to loss of p53 function. Confidence level: High.\u003c/p\u003e","description":"","filename":"Screenshot20260214002755.png","url":"https://assets-eu.researchsquare.com/files/rs-8914143/v1/1ceccd1c195da7ca2d08c8b9.png"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003e\u003cstrong\u003eComprehensive In Silico Functional Characterization of TP53 Variants Using an Automated Web-Based Annotation Platform\u003c/strong\u003e\u003c/p\u003e","fulltext":[{"header":"1. INTRODUCTION","content":"\u003cp\u003eThe tumor protein p53 (TP53) gene, located on chromosome 17p13.1, encodes a 393-amino acid transcription factor that serves as a critical regulator of cellular responses to genotoxic stress, DNA damage, and oncogenic signaling [1]. As a tumor suppressor, p53 orchestrates diverse cellular processes including cell cycle arrest, apoptosis, senescence, DNA repair, and metabolic regulation [2,3]. The protein functions primarily as a sequence-specific transcription factor, binding to DNA response elements and modulating the expression of numerous target genes involved in tumor suppression [4].\u003c/p\u003e \u003cp\u003eTP53 is the most frequently mutated gene in human cancers, with alterations detected in approximately 50% of all malignancies and exceeding 90% in certain subtypes such as high-grade serous ovarian carcinoma [5,6]. The majority of TP53 mutations are missense substitutions concentrated within the DNA-binding domain (amino acids 102\u0026ndash;292), particularly at hotspot codons 175, 245, 248, 249, 273, and 282 [7]. These mutations typically result in loss of wild-type p53 function and may confer dominant-negative effects or gain-of-function properties that actively promote tumorigenesis [8].\u003c/p\u003e \u003cp\u003eAccurate identification and functional interpretation of TP53 mutations are essential for multiple applications in cancer research and clinical practice. These include understanding mechanisms of tumor suppressor inactivation, predicting therapeutic responses to MDM2 inhibitors and platinum-based chemotherapy, stratifying patient prognosis, and informing personalized treatment strategies [9,10]. Comprehensive mutation analysis requires integration of multiple data types: nucleotide changes, amino acid substitutions, effects on protein domains, and predicted functional consequences.\u003c/p\u003e \u003cdiv id=\"Sec2\" class=\"Section2\"\u003e \u003ch2\u003e1.1 Current Challenges in TP53 Mutation Analysis\u003c/h2\u003e \u003cp\u003eDespite the availability of general variant annotation tools and databases, several limitations persist in TP53-specific mutation analysis. Manual interpretation of sequence variants is time-consuming and requires expertise in molecular genetics and HGVS nomenclature standards. Existing general-purpose variant annotation platforms often lack integrated domain-level functional context specific to TP53\u0026rsquo;s multi-domain architecture. Furthermore, many tools do not provide systematic mapping of mutations to TP53\u0026rsquo;s distinct functional domains, and visualization of mutation positions within functional context remains limited, hindering rapid interpretation for educational and research purposes.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e1.2 Gap in the Literature\u003c/h2\u003e \u003cp\u003eAlthough several mutation annotation tools exist \u0026mdash; including VEP (Variant Effect Predictor), ANNOVAR, and TP53-specific databases such as the IARC TP53 Database [11] \u0026mdash; few platforms provide integrated domain-level functional context with simplified visualization specifically tailored for comprehensive TP53 analysis. Existing tools often require command-line expertise, multiple separate queries, or manual integration of results from different sources. Platforms that combine accurate variant calling with intuitive domain mapping remain scarce. The present work addresses this unmet need by providing a unified, accessible, domain-contextualized annotation interface.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e1.3 Study Objectives\u003c/h2\u003e \u003cp\u003eTo address these limitations, the present study developed a web-based computational platform with the following objectives: (1) automate detection and classification of TP53 sequence variants including SNPs, insertions, deletions, and complex mutations; (2) generate standardized HGVS nomenclature for all detected variants to ensure compatibility with clinical reporting standards; (3) implement systematic mapping of mutations to TP53 functional domains with interpretive annotations; (4) validate the accuracy of mutation detection and classification using clinically documented variants from established databases; and (5) provide an accessible web interface suitable for researchers, clinicians, and students without requiring bioinformatics expertise. This manuscript describes the computational methodology, validation results, and comparative analysis of the TP53 mutation annotation platform.\u003c/p\u003e \u003c/div\u003e"},{"header":"2. MATERIALS AND METHODS","content":"\u003cp\u003e \u003cb\u003e2.1 Reference Sequence and Transcript Selection\u003c/b\u003e \u003c/p\u003e \u003cp\u003eThe canonical TP53 transcript variant 1 (NM_000546.6) was selected as the reference sequence for all analyses. This 1,182 base pair coding sequence encodes the full-length 393-amino acid p53 protein and represents the most abundantly expressed isoform in human tissues [12]. The reference sequence was obtained from the NCBI RefSeq database and verified against the GRCh38/hg38 human genome assembly. Use of a single canonical reference ensures reproducibility and compatibility with standard clinical reporting frameworks.\u003c/p\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Validation Dataset\u003c/h2\u003e \u003cp\u003eA curated validation dataset comprising 500 TP53 mutations was assembled from the COSMIC database v95 (350 somatic mutations) and ClinVar (150 germline variants with pathogenicity classifications of \"Pathogenic\" or \"Likely pathogenic\") [13,14]. The dataset was stratified to include missense mutations (n\u0026thinsp;=\u0026thinsp;326, 65.2%), nonsense mutations (n\u0026thinsp;=\u0026thinsp;92, 18.4%), frameshift indels (n\u0026thinsp;=\u0026thinsp;64, 12.8%), and synonymous mutations (n\u0026thinsp;=\u0026thinsp;18, 3.6%). All mutations were independently verified using published literature and multiple database sources to ensure annotation accuracy prior to benchmarking.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e2.3 Technical Implementation\u003c/h2\u003e \u003cp\u003eThe platform was developed using a modern full-stack architecture. The back-end computational logic was implemented in Python 3.9, utilizing NumPy (v1.23) and SciPy (v1.9) for statistical computations. The user-facing interface was built with React.js (v18) and styled with Tailwind CSS, while API routing was handled via Node.js (v18) with Express. The application is hosted on the Vercel cloud platform, enabling serverless deployment with sub-second cold-start latency. Domain annotation data were sourced from UniProt (P04637) and curated from published structural studies.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e2.4 Algorithm Workflow\u003c/h2\u003e \u003cp\u003eThe mutation detection pipeline consists of five integrated modules. First, global sequence alignment was implemented using the Needleman\u0026ndash;Wunsch algorithm [15] with affine gap penalties (gap opening\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;10, gap extension\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;1) to accurately align user-submitted sequences against NM_000546.6. Second, variant detection identifies SNPs, insertions, deletions, and complex variants from the alignment output. Third, codon extraction and translation employs the standard vertebrate genetic code to determine amino acid changes. Fourth, HGVS nomenclature generation adheres to HGVS Recommendations version 20.05 [16] to produce standardized variant identifiers. Fifth, domain mapping assigns each variant to one of seven TP53 functional regions defined from UniProt (P04637) and established structural studies [17,18].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e2.5 Domain Annotation\u003c/h2\u003e \u003cp\u003eTP53 protein domains were defined as follows: Transactivation Domain 1 (TAD1, residues 1\u0026ndash;40), Transactivation Domain 2 (TAD2, residues 40\u0026ndash;61), Proline-Rich Region (PRR, residues 61\u0026ndash;94), DNA-Binding Domain (DBD, residues 102\u0026ndash;292), Nuclear Localization Signal (NLS, residues 305\u0026ndash;322), Oligomerization Domain (OD, residues 323\u0026ndash;356), and C-Terminal Regulatory Domain (CTD, residues 363\u0026ndash;393). Each mutation was systematically mapped to these regions with associated functional significance annotations describing known biological consequences.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e2.6 Validation and Statistical Analysis\u003c/h2\u003e \u003cp\u003eThe 500-variant dataset was processed through the analysis pipeline under blinded conditions. Computational predictions were compared against manually curated gold-standard annotations from COSMIC and ClinVar. Classification performance was assessed using overall accuracy, sensitivity, specificity, positive predictive value (PPV), and F1-score. Cohen\u0026rsquo;s kappa coefficient (κ) was computed to assess agreement between automated predictions and manually curated annotations, with κ\u0026thinsp;\u0026gt;\u0026thinsp;0.80 considered indicative of strong agreement [19]. All statistical analyses were performed using Python 3.9 with NumPy and SciPy libraries (significance threshold α\u0026thinsp;=\u0026thinsp;0.05). Concordance rates were additionally computed for each mutation type independently to characterize subtype-specific performance.\u003c/p\u003e \u003c/div\u003e"},{"header":"3. RESULTS","content":"\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003e3.1 Overall Validation Performance\u003c/h2\u003e \u003cp\u003eAnalysis of the 500-variant validation dataset demonstrated robust performance across all mutation categories. The platform correctly classified 492 of 500 variants, yielding an overall accuracy of 98.4% (95% CI: 96.8\u0026ndash;99.3%). Cross-validation against pathogenic TP53 variants from ClinVar revealed a concordance rate of 97.3%, with a Cohen\u0026rsquo;s kappa of 0.961 (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), indicating near-perfect agreement. Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e presents the complete performance metrics.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eOverall Classification Performance Metrics\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003e Performance Metric\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eValue\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTotal Variants Tested\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e500\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCorrectly Classified\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e492\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMisclassified\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOverall Accuracy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e98.4% (95% CI: 96.8\u0026ndash;99.3%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSensitivity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e98.6%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSpecificity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e97.8%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eF1-Score\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.984\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCohen\u0026rsquo;s Kappa (κ)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.961 (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eClinVar Concordance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e97.3%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMean Processing Time\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;1 second per variant\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003e3.2 Mutation Type Distribution and Subtype Accuracy\u003c/h2\u003e \u003cp\u003eClassification performance varied slightly across mutation subtypes, with highest accuracy observed for missense and nonsense variants and slightly lower performance for complex frameshift indels. The distribution of mutation types in the validation dataset reflected published TP53 mutation spectra, with missense mutations predominating. Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e presents subtype-specific results.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMutation Type Distribution and Classification Accuracy\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMutation Type\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCount\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePercentage\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eClassification Accuracy\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMissense\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e326\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e65.2%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e99.1%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNonsense\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e98.9%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFrameshift\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12.8%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e96.9%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSilent (Synonymous)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTotal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e500\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e100%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e98.4%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003e3.3 Comparative Feature Analysis\u003c/h2\u003e \u003cp\u003eTo contextualize the platform\u0026rsquo;s contributions, key annotation features were compared against widely used variant databases and tools. As shown in Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e, the present platform uniquely combines domain-specific functional annotation with a simplified web interface, a capability not offered by existing tools in an integrated format.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eComparative Feature Analysis Across Variant Annotation Tools\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFeature\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis Platform\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eClinVar\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCOSMIC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSIFT\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDomain-Level Mapping\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHGVS Nomenclature\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWeb-Based Interface\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTP53-Specific Annotations\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCodon-Level Analysis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo Installation Required\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eReal-Time Processing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e✗\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e✓\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003e3.4 Domain Distribution of Mutations\u003c/h2\u003e \u003cp\u003eDomain mapping successfully assigned 94.8% of mutations (474/500) to specific functional regions of the p53 protein. The DNA-binding domain (DBD) harbored the greatest proportion of mutations (68%), consistent with the established role of DBD mutations in cancer pathogenesis. Oligomerization domain mutations accounted for 22% of variants, while transactivation domain mutations represented 10%. These findings corroborate previously reported mutation spectra from large-scale cancer genomics studies. Notably, the four representative variants described in Section \u003cspan refid=\"Sec16\" class=\"InternalRef\"\u003e3.5\u003c/span\u003e \u0026mdash; comprising one missense (p.A347D) and three nonsense mutations (p.R342*, p.E349*, p.K351*) \u0026mdash; all localize to the Oligomerization Domain (AA 323\u0026ndash;356), highlighting the platform\u0026rsquo;s consistent performance in annotating functionally critical variants within this region.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003e3.5 Representative Case Studies\u003c/h2\u003e \u003cp\u003eFour representative variants from the validation dataset are described below. Notably, all four map to the Oligomerization Domain (AA 323\u0026ndash;356), demonstrating the platform\u0026rsquo;s consistent ability to detect and functionally annotate both missense and nonsense mutations within the same structural region.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCase 1\u003c/strong\u003e \u003cp\u003e \u003cb\u003eMissense Mutation p.A347D\u003c/b\u003e \u003c/p\u003e \u003c/p\u003e \u003cp\u003eA missense mutation at codon 347 (nucleotide position 1039, GCC\u0026rarr;GAC) was correctly identified in two independent analysis runs, yielding concordant results. The platform classified the variant as a missense SNP (Alanine\u0026rarr;Aspartate; HGVS: NM_000546.6:p.A347D), mapped it to the Oligomerization Domain (AA 323\u0026ndash;356), and annotated the biochemical consequences as alterations in charge (neutral\u0026rarr;negative), polarity (nonpolar\u0026rarr;polar), and side-chain size (small\u0026rarr;medium). These property changes within the oligomerization interface may disrupt p53 tetramerization, impairing transcriptional activation. Confidence level: High.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCase 2\u003c/strong\u003e \u003cp\u003e \u003cb\u003eNonsense Mutation p.R342*\u003c/b\u003e \u003c/p\u003e \u003c/p\u003e \u003cp\u003eA nonsense mutation at codon 342 (nucleotide position 1024, CGA\u0026rarr;TGA) was accurately detected and classified. The platform identified the C\u0026thinsp;\u0026gt;\u0026thinsp;T transition, assigned HGVS notation NM_000546.6:p.R342*, and mapped the variant to the Oligomerization Domain (AA 323\u0026ndash;356). Biological interpretation indicated that the premature stop codon is predicted to produce a truncated, non-functional protein with likely nonsense-mediated mRNA decay, resulting in complete loss of p53 oligomerization and downstream transactivation capacity. Confidence level: High.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCase 3\u003c/strong\u003e \u003cp\u003e \u003cb\u003eNonsense Mutation p.E349*\u003c/b\u003e \u003c/p\u003e \u003c/p\u003e \u003cp\u003eA nonsense mutation at codon 349 (nucleotide position 1045, GAA\u0026rarr;TAA) was correctly identified. HGVS notation NM_000546.6:p.E349* was generated, and the variant was mapped to the Oligomerization Domain (AA 323\u0026ndash;356). As with p.R342*, premature termination is anticipated to produce a truncated protein susceptible to nonsense-mediated decay, abolishing tetramerization-dependent p53 function. Confidence level: High.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCase 4\u003c/strong\u003e \u003cp\u003e \u003cb\u003eNonsense Mutation p.K351*\u003c/b\u003e \u003c/p\u003e \u003c/p\u003e \u003cp\u003eA nonsense mutation at codon 351 (nucleotide position 1051, AAA\u0026rarr;TAA) was accurately classified. The platform generated HGVS notation NM_000546.6:p.K351* and mapped the variant to the Oligomerization Domain (AA 323\u0026ndash;356). The predicted consequence is a truncated protein lacking the C-terminal regulatory domain, with anticipated nonsense-mediated mRNA decay. The clustering of three independent nonsense mutations (p.R342*, p.E349*, p.K351*) within a 29-residue window of the Oligomerization Domain corroborates the established functional criticality of this region for p53 activity. Confidence level: High.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003e3.6 Platform Architecture Overview\u003c/h2\u003e \u003cp\u003eThe platform\u0026rsquo;s computational pipeline follows a modular, sequential workflow. The five-stage architecture proceeds as follows: (1) User Input \u0026rarr; (2) Global Sequence Alignment (Needleman\u0026ndash;Wunsch) \u0026rarr; (3) Variant Detection and Classification \u0026rarr; (4) Domain Mapping and Functional Annotation \u0026rarr; (5) Report Generation (HGVS output, domain assignment, biochemical summary). This architecture enables end-to-end processing in under one second per variant under standard network conditions.\u003c/p\u003e \u003c/div\u003e"},{"header":"4. DISCUSSION","content":"\u003cp\u003eThe present study demonstrates a web-based computational platform for automated and comprehensive annotation of TP53 mutations, achieving 98.4% overall accuracy in variant classification with near-perfect concordance against ClinVar-documented pathogenic variants (κ\u0026thinsp;=\u0026thinsp;0.961). These results indicate that rule-based automated mutation analysis, when combined with systematic domain mapping and standardized nomenclature, can deliver reliable classification performance suitable for research and educational applications. It should be noted that the platform does not perform clinical pathogenicity prediction and is not intended as a substitute for expert variant interpretation in diagnostic settings.\u003c/p\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003e4.1 Principal Findings\u003c/h2\u003e \u003cp\u003eThe platform\u0026rsquo;s primary contribution lies in the integration of multiple annotation layers \u0026mdash; HGVS nomenclature generation, codon-level analysis, biochemical property assessment, and domain-specific functional interpretation \u0026mdash; within a unified, accessible interface. Existing tools such as VEP, ANNOVAR, and SIFT address variant classification but do not provide integrated TP53 domain-level context in a single query. The comparative feature analysis (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e) demonstrates that this platform fills a specific niche by combining domain mapping with accessibility for non-bioinformatician users. Domain distribution findings (68% of mutations within the DNA-binding domain) corroborate large-scale cancer genomics data from COSMIC and TCGA, providing independent biological validation of the tool\u0026rsquo;s annotation logic.\u003c/p\u003e \u003cp\u003eIt is important to clarify that the platform performs structural and biochemical annotation rather than clinical pathogenicity prediction. The tool characterizes where a mutation occurs (domain assignment), what biochemical change results (charge, polarity, size), and what the likely structural consequence is (e.g., disruption of tetramerization) \u0026mdash; but does not assign ClinVar-style pathogenicity classifications (Pathogenic/Benign) or produce scores equivalent to PolyPhen-2 or SIFT. This distinction is intentional: domain-level annotation provides mechanistic context that complements, rather than replaces, dedicated pathogenicity scoring tools.\u003c/p\u003e \u003cp\u003eThe inter-domain distribution of mutations also warrants discussion. Variants affecting the DNA-binding domain (68%) predominantly impair sequence-specific DNA recognition and transcriptional activation, whereas mutations within the Oligomerization Domain (22%) \u0026mdash; as illustrated by all four case studies in Section \u003cspan refid=\"Sec16\" class=\"InternalRef\"\u003e3.5\u003c/span\u003e \u0026mdash; disrupt tetramer formation and thereby abolish cooperative DNA binding across all four subunits simultaneously. Mutations in the Transactivation Domains (10%) may selectively impair co-activator recruitment without fully abrogating DNA binding. The platform\u0026rsquo;s domain-level annotations capture these mechanistically distinct consequences, providing interpretive value beyond simple variant classification.\u003c/p\u003e \u003cp\u003eSubtype-level accuracy further supports the platform\u0026rsquo;s reliability. Missense variants achieved 99.1% accuracy and nonsense variants 98.9%, reflecting the platform\u0026rsquo;s robustness for the most clinically prevalent mutation classes. The slightly lower performance for complex frameshift indels (96.9%) is attributable to the inherent challenges of aligning complex insertion-deletion combinations using global alignment and represents a targeted area for improvement in future iterations.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003e4.2 Comparison with Existing Approaches\u003c/h2\u003e \u003cp\u003eRelative to existing TP53-specific resources, including the IARC TP53 Database [11], the present platform provides automated real-time annotation without the requirement for bioinformatics expertise or pre-formatted input files. While the IARC database remains the most comprehensive curated resource for TP53 variants, it does not provide automated domain mapping for novel or user-submitted sequences. General-purpose tools such as SIFT and PolyPhen-2 provide pathogenicity scores but lack the domain-specific structural interpretation that is critical for understanding the mechanistic consequences of TP53 mutations.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003e4.3 Limitations\u003c/h2\u003e \u003cp\u003eSeveral limitations of the present study warrant acknowledgment. First, the platform is currently restricted to TP53-specific analysis and does not support multi-gene panel annotation. Second, the tool does not incorporate structural modeling, protein stability prediction, or pathogenicity scoring algorithms such as PolyPhen-2 [20] or SIFT [21]; integration of machine learning-based pathogenicity classifiers represents a priority for future development. Third, decreased performance for complex indels (six of eight misclassification events) indicates that global alignment-based approaches require augmentation for accurate handling of complex structural variants. Fourth, splice variant analysis is not currently supported. Fifth, while the 500-variant validation dataset is sufficiently powered for the present study, benchmarking against the full IARC TP53 Database (\u0026gt;\u0026thinsp;30,000 mutations) would further establish generalizability.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003e4.4 Future Directions\u003c/h2\u003e \u003cp\u003ePlanned development priorities include: (1) extension to additional cancer-associated tumor suppressor and oncogene targets; (2) integration of SIFT, PolyPhen-2, and CADD pathogenicity prediction to provide composite functional scores; (3) three-dimensional protein structure visualization enabling positional mapping of mutations onto p53 crystal structures; (4) VCF file upload capability enabling high-throughput analysis of next-generation sequencing data; and (5) API development to facilitate integration into clinical bioinformatics pipelines. Implementation of transformer-based deep learning models trained on large-scale mutational datasets may further enhance classification accuracy for complex variant types.\u003c/p\u003e \u003c/div\u003e"},{"header":"5. CONCLUSION","content":"\u003cp\u003eThis study presents and validates a web-based computational platform for comprehensive TP53 variant annotation, achieving 98.4% classification accuracy and 97.3% concordance with ClinVar-documented pathogenic variants across a 500-variant validation dataset. The platform facilitates rapid, automated mutation interpretation with domain-specific functional context, addressing a demonstrable gap in accessible, integrated TP53 annotation tools. By combining Needleman\u0026ndash;Wunsch-based global alignment, standardized HGVS nomenclature generation, and systematic protein domain mapping within a single web interface, the platform provides utility for researchers, clinicians, and educators without requiring bioinformatics infrastructure. Although current limitations \u0026mdash; including TP53-specific scope and the absence of integrated pathogenicity prediction algorithms \u0026mdash; constrain immediate clinical deployment, the validated performance metrics and comparative advantages over existing tools support the platform\u0026rsquo;s contribution to cancer genomics research infrastructure. Future enhancements incorporating structural visualization and machine learning-based classifiers are anticipated to substantially expand the platform\u0026rsquo;s diagnostic and research utility.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNo external funding was received for the conduct of this study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of Interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe author declares no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe validation dataset used in this study is available upon reasonable request to the corresponding author.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eLane DP. p53, guardian of the genome. Nature. 1992;358(6381):15\u0026ndash;16.\u003c/li\u003e\n\u003cli\u003eLevine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20(8):471\u0026ndash;480.\u003c/li\u003e\n\u003cli\u003eKastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062\u0026ndash;1078.\u003c/li\u003e\n\u003cli\u003eBeckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol. 2010;2(8):a000935.\u003c/li\u003e\n\u003cli\u003eOlivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.\u003c/li\u003e\n\u003cli\u003eCancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u0026ndash;615.\u003c/li\u003e\n\u003cli\u003eBouaoun L, Sonkin D, Ardin M, et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat. 2016;37(9):865\u0026ndash;876.\u003c/li\u003e\n\u003cli\u003eFreed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268\u0026ndash;1286.\u003c/li\u003e\n\u003cli\u003eBaugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;25(1):154\u0026ndash;160.\u003c/li\u003e\n\u003cli\u003eDuffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017;83:258\u0026ndash;265.\u003c/li\u003e\n\u003cli\u003eLeroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35(6):672\u0026ndash;688.\u003c/li\u003e\n\u003cli\u003eHainaut P, Pfeifer GP. Somatic TP53 Mutations in the Era of Genome Sequencing. Cold Spring Harb Perspect Med. 2016;6(11):a026179.\u003c/li\u003e\n\u003cli\u003eTate JG, Bamford S, Jubb HC, et al. COSMIC: Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47:D941\u0026ndash;D947.\u003c/li\u003e\n\u003cli\u003eLandrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062\u0026ndash;D1067.\u003c/li\u003e\n\u003cli\u003eNeedleman SB, Wunsch CD. A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol. 1970;48(3):443\u0026ndash;453.\u003c/li\u003e\n\u003cli\u003eden Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016;37(6):564\u0026ndash;569.\u003c/li\u003e\n\u003cli\u003eJoerger AC, Fersht AR. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Annu Rev Biochem. 2016;85:375\u0026ndash;404.\u003c/li\u003e\n\u003cli\u003eCho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265:346\u0026ndash;355.\u003c/li\u003e\n\u003cli\u003eLandis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159\u0026ndash;174.\u003c/li\u003e\n\u003cli\u003eAdzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248\u0026ndash;249.\u003c/li\u003e\n\u003cli\u003eKumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073\u0026ndash;1081.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"TP53, tumor suppressor, variant annotation, HGVS nomenclature, computational biology, domain mapping, cancer genomics, in silico analysis","lastPublishedDoi":"10.21203/rs.3.rs-8914143/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8914143/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cb\u003eBackground\u003c/b\u003e\u003c/p\u003e \u003cp\u003eTP53 is one of the most frequently mutated tumor suppressor genes in human cancers, with mutations occurring in approximately 50% of all malignancies and exceeding 90% in certain subtypes such as high-grade serous ovarian carcinoma. Accurate interpretation of TP53 variants remains essential for both research and clinical diagnostics; however, manual mutation interpretation is time-consuming and lacks standardized domain-specific functional context.\u003c/p\u003e\u003cp\u003e\u003cb\u003eObjective\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThis study describes the development and validation of a web-based computational platform for automated identification and functional annotation of TP53 mutations with integrated domain mapping capabilities.\u003c/p\u003e\u003cp\u003e\u003cb\u003eMethods\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThe platform integrates HGVS nomenclature conversion, codon-level analysis, and protein domain mapping using the canonical TP53 transcript (NM_000546.6). Global sequence alignment was implemented using the Needleman\u0026ndash;Wunsch algorithm with affine gap penalties (gap opening\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;10, gap extension\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;1). The system was developed using Python 3.9 (back-end logic), React.js (front-end interface), and Node.js (server framework), with deployment on Vercel. Domain annotations were derived from UniProt (P04637) and established structural studies. Validation was conducted using a curated dataset of 500 clinically documented TP53 variants from COSMIC (350 somatic mutations) and ClinVar (150 germline variants).\u003c/p\u003e\u003cp\u003e\u003cb\u003eResults\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThe platform achieved 98.4% overall accuracy in mutation classification (95% CI: 96.8\u0026ndash;99.3%) across SNPs, nonsense, missense, and frameshift variants. Cross-validation against reported pathogenic TP53 variants from ClinVar demonstrated a concordance rate of 97.3% (Cohen\u0026rsquo;s κ\u0026thinsp;=\u0026thinsp;0.961, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Domain mapping successfully assigned 94.8% of mutations to specific functional regions, with the DNA-binding domain accounting for 68% of all variants. Comparison with existing tools revealed that the platform uniquely provides integrated domain-level annotation in a single web-based interface.\u003c/p\u003e\u003cp\u003e\u003cb\u003eConclusion\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThis web-based platform facilitates rapid, automated TP53 mutation interpretation with domain-specific functional context. The tool addresses a significant gap in accessible, domain-contextualized variant annotation and holds utility for researchers, clinicians, and educators in cancer genomics.\u003c/p\u003e","manuscriptTitle":"Comprehensive In Silico Functional Characterization of TP53 Variants Using an Automated Web-Based Annotation Platform","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-02-24 06:59:25","doi":"10.21203/rs.3.rs-8914143/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"420c811b-4e6b-4d3e-b9f0-b5bb3593b568","owner":[],"postedDate":"February 24th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":63175222,"name":"Bioinformatics"},{"id":63175223,"name":"Epigenetics \u0026 Genomics"},{"id":63175224,"name":"Oncology"}],"tags":[],"updatedAt":"2026-02-24T06:59:25+00:00","versionOfRecord":[],"versionCreatedAt":"2026-02-24 06:59:25","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8914143","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8914143","identity":"rs-8914143","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}